Acurx Pharmaceuticals, Inc.
ACXP· Nasdaq
ACXPAcurx Pharmaceuticals, Inc.
Filed Nov 12, 2024 · 10-Q · 43 days after period end · 0001558370-24-015310
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Net Income | -$2.82M | -$3.11M | -$3.54M | -$4.64M |
| EPS Diluted | -$3.45 | -$0.24 | -$0.32 | -$0.46 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acurx Pharmaceuticals, Inc. · CIK 1736243 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d after period end
